Amylyx Pharmaceuticals Inc has raised $5 million with a Series A equity placement that will top up its financing for a Phase 2 study of AMX0035, an experimental treatment for amyotrophic lateral sclerosis (ALS). ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
